AZNCF News and Press, AstraZeneca Plc From 08/07/20

The art of medicine consists of amusing the patient while nature cures the disease. ― Voltaire At first glance, Tekla World Healthcare Fund ( THW ) looks like a solid dividend bet because it has been paying dividends consistently since inception and it sports an attractive dividend ...

Quick Take CureVac B.V. ( CVAC ) has filed to raise $100 million in an IPO of its common shares, according to an F-1 registration statement . The firm is developing a wide range of treatments, vaccines and therapies based on messenger RNA technologies. CVAC has developed extensive colla...

Quick Take Checkmate Pharmaceuticals ( CMPI ) intends to raise $75 million from the sale of its common stock stock in an IPO, according to an amended registration statement . The company is advancing a biologic particle treatment for melanomas and head & neck squamous cell carcinomas....

AstraZeneca reports positive data for nirsevimab AstraZeneca (AZN) announced positive data for nirsevimab for the passive immunization against respiratory syncytial virus ((RSV)) infections in healthy preterm infants. The data showed that the treatment was able to provide favorable resul...

Quick Take Checkmate Pharmaceuticals ( CMPI ) has filed to raise $75 million in an IPO of its common stock, according to an S-1 registration statement . The company is a clinical stage biopharma advancing a drug treatment candidate for melanoma and head & neck cancer. CMPI has produ...

AstraZeneca PLC (AZN) Q2 2020 Earnings Conference Call July 30, 2020, 06:45 ET Company Participants Pascal Soriot - CEO David Fredrickson - EVP, Oncology Business Unit Ruud Dobber - EVP, BioPharmaceuticals Business Unit Marc Dunoyer - CFO José Baselga - EVP, Oncology Res...

The following slide deck was published by AstraZeneca PLC in conjunction with their 2020 Q2 earnings Read more ...

Amgen reports better than expected Q2 numbers, raises guidance Amgen ( AMGN ) reported its second quarter earnings, generally besting the market estimates. The company’s earnings per share stood at $4.25, up 7.05 percent on a year-over-year basis. It also surpassed the market expe...

Source: Explained: The challenges in developing a COVID-19 vaccine The COVID pandemic has destroyed global economies and this had led to an open checkbook in the search for a vaccine. However, in science facts matter and the size of the spend doesn’t guarantee success. Things ar...

Biotech Pulse Biotechs continue to be one of the leading healthcare groups and along with diagnostics represent two of the best segments of healthcare. The first half saw biotechs recover quicker from the March selloff than most of the market, and reach a milestone that took 5 years to achie...